In vitro analyses of the anti-fibrotic effect of SPARC silencing in human Tenon's fibroblasts: Comparisons with mitomycin C

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 6, 2012, Pages 1245-1259

  Seet, Li Fong ^a   Su, Roseline ^a   Toh, Li Zhen ^a   Wong, Tina T ^a,b,c,d  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Conjunctiva; Fibrosis; Glaucoma; Mitomycin C; SPARC

Indexed keywords

CCL2 PROTEIN, HUMAN; COLLAGEN TYPE 1; FIBRONECTIN; GELATINASE A; GELATINASE B; INTERLEUKIN 8; MATRIX METALLOPROTEINASE 14; MITOMYCIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEONECTIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA2;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; FIBROBLAST; FIBROSIS; GENE SILENCING; GENETICS; HUMAN; METABOLISM; NICK END LABELING; REAL TIME POLYMERASE CHAIN REACTION; SCAR; TENON CAPSULE; WOUND HEALING;

APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; CICATRIX; COLLAGEN TYPE I; FIBROBLASTS; FIBRONECTINS; FIBROSIS; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; IN SITU NICK-END LABELING; INTERLEUKIN-8; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MITOMYCIN; OSTEONECTIN; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TENON CAPSULE; TRANSFORMING GROWTH FACTOR BETA2; WOUND HEALING;

MURINAE; MUS;

EID: 84861559414     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01400.x     Document Type: Article

References (54)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90: 262-7.
2. Heijl A, Leske MC, Bengtsson B. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002; 120: 1268-78.
3. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120: 701-13.
4. Hitchings RA, Grierson I. Clinico pathological correlation in eyes with failed fistulizing surgery. Trans Ophthalmol Soc UK 1983; 103: 84-8.
5. Skuta GL, Parrish RK 2nd. Wound healing in glaucoma filtering surgery. Surv Ophthalmol. 1987; 32: 149-70.
6. Jampel HD, McGuigan LJ, Dunkelberger GR, et al. Cellular proliferation after experimental glaucoma filtration surgery. Arch Ophthalmol. 1988; 106: 89-94.
7. Saika S, Yamanaka O, Baba Y, et al. Accumulation of latent transforming growth factor-beta binding protein-1 and TGF beta 1 in extracellular matrix of filtering bleb and of cultured human subconjunctival fibroblasts. Graefes Arch Clin Exp Ophthalmol. 2001; 239: 234-41.
8. Broadway DC, Bates AK, Lightman SL, et al. The importance of cellular changes in the conjunctiva of patients with uveitic glaucoma undergoing trabeculectomy. Eye. 1993; 7: 495-501.
9. Yaldo MK, Stamper RL. Long-term effects of mitomycin on filtering blebs. Lack of fibrovascular proliferative response following severe inflammation. Arch Ophthalmol. 1993; 111: 824-6.
10. Chang L, Crowston JG, Sabin CA, et al. Human tenon's fibroblast-produced IFNβ and the prevention of T cell apoptosis. Invest Ophthalmol Vis Sci. 2001; 42: 1531-8.
11. Khaw PT, Doyle JW, Sherwood MB, et al. Prolonged localized tissue effects from 5-minute exposures to fluouracil and mitomycin C. Arch Ophthalmol. 1993; 111: 263-7.
12. Crowston JG, Chang LH, Constable PH, et al. Apoptosis gene expression and death receptor signaling in mitomycin-C-treated human tenon capsule fibroblasts. Invest Ophthalmol Vis Sci. 2002; 43: 692-9.
13. Crowston JG, Chang LH, Daniels JT, et al. T lymphocyte mediated lysis of mitomycin C treated Tenon's capsule fibroblasts. Br J Ophthalmol. 2004; 88: 399-405.
14. Occleston NL, Daniels JT, Tarnuzzer RW, et al. Single exposures to antiproliferatives: long-term effects on ocular fibroblasts wound-healing behavior. Invest Ophthalmol Vis Sci. 1997; 38: 1998-2007.
15. Radcliffe NM. Trabeculectomy revision as a treatment for failed trabeculectomy. Glaucoma Today; Fall 2010: 25-8.
16. Greenfield DS, Suner IJ, Miller MP. Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol. 1996; 114: 943-9.
17. Higginbotham EJ, Stevens RK, Musch DC. Bleb-related endophthalmitis after trabeculectomy with mitomycin C. Ophthalmol. 1996; 103: 650-6.
18. Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol. 2002; 14: 608-16.
19. Seet LF, Su R, Barathi VA, et al. SPARC deficiency results in improved surgical survival in a novel mouse model of glaucoma filtration surgery. PLoS One 2010; 5: e9415.
20. Scheuermann T, Sun Y, Sagner S, Rueger B. Gene Expression analysis of paclitaxel-treated HT29 cells using the xCELLigence™ system and realtime ready™ panels. Biotechniques 2009; 46: 557-8.
21. Grinnell F. Fibroblasts, myofibroblasts, and wound contraction. J Cell Biol. 1994; 124: 401-4.
22. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-5.
23. Chou SF, Chang SW, Chuang JL. Mitomycin C upregulates IL-8 and MCP-1 chemokine expression via mitogen-activated protein kinases in corneal fibroblasts. Invest Ophthalmol Vis Sci. 2007; 48: 2009-16.
24. Strandjord TP, Madtes DK, Weiss DJ, et al. Collagen accumulation is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis. Am J Physiol. 1999; 277: 628-35.
25. Lee DA. Antifibrosis agents and glaucoma surgery. Invest Ophthalmol Vis Sci. 1994; 35: 3789-91.
26. Seet LF, Lee WS, Su R, et al. Validation of the glaucoma filtration surgical mouse model for anti-fibrotic drug evaluation. Mol Med. 2011; 17: 557-67.
27. Jampel HD, Pasquale LR, Dibernardo C. Hypotony maculopathy following trabeculectomy with mitomycin C. Arch Ophthalmol. 1992; 110: 1049-50.
28. Parrish R, Minckler D. "Late endophthalmitis": filtering surgery time bomb?Ophthalmology 1996; 103: 1167-8.
29. Rollins BJ. Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today 1996; 2: 198-204.
30. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and (MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol. 1999; 117: 159-65.
31. Distler O, Pap T, Kowal-Bielecka O, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum. 2001; 44: 2665-78.
32. Yamamoto T, Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol. 2003; 121: 510-6.
33. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem. 1996; 271: 17779-84.
34. Ferreira AM, Takagawa S, Fresco R, et al. Diminished induction of skin fibrosis in mice with MCP-1 Deficiency. J Invest Dermatol. 2006; 126: 1900-8.
35. Martinek N, Shahab J, Sodek J, et al. Is SPARC an evolutionarily conserved collagen chaperone?J Dent Res. 2007; 86: 296-305.
36. Rentz TJ, Poobalarahi F, Bornstein P, et al. SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts. J Biol Chem. 2007; 282: 22062-71.
37. Basu A, Kligman LH, Samulewicz SJ, et al. Impaired wound healing in mice deficient in a matricellular protein SPARC (osteonectin, BM-40). BMC Cell Biol. 2001; 2: 15.
38. Seno T, Harada H, Kohno S, et al. Downregulation of SPARC expression inhibits cell migration and invasion in malignant gliomas. Int J Oncol. 2009; 34: 707-15.
39. Gilles C, Bassuk JA, Pulyaeva H, et al. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res. 1998; 58: 5529-36.
40. McClung HM, Thomas SL, Osenkowski P, et al. SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of Galectin-3 in U87MG glioma cells. Neurosci Lett. 2007; 419: 172-7.
41. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007; 8: 221-33.
42. Harris AK, Stopak D, Wild P. Fibroblast traction as a mechanism for collagen morphogenesis. Nature. 1981; 290: 249-51.
43. Grinnell F. Fibroblast biology in three-dimensional collagen matrices. Trends Cell Biol. 2003; 13: 264-9.
44. Mauch C, Adelmann-Grill B, Hatamochi A, et al. Collagenase gene expression in fibroblasts is regulated by a three-dimensional contact with collagen. Fed Europ Biochem Soc. 1989; 250: 301-5.
45. Langholz O, Rockel D, Mauch C, et al. Collagen and collagenase gene expression in three-dimensional collagen lattices are differentially regulated by α1β1 and α2 β1 integrins. J Cell Biol. 1995; 131: 1903-15.
46. Van Winkle WJr. The tensile strength of wounds and factors that influence it. Surg Gynecol Obstet. 1969; 129: 819-42.
47. Bell E, Ivarsson B, Merrill C. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc Natl Acad Sci USA 1979; 76: 1274-8.
48. Daniels JT, Cambrey AD, Occleston NL, et al. Matrix metalloproteinase inhibition modulates fibroblast-mediated matrix contraction and collagen production in vitro. Invest Ophthalmol Vis Sci. 2003; 44: 1104-10.
49. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 2007; 117: 524-9.
50. Fuller JR, Bevin TH, Molteno ABC, et al. Anti-inflammatory fibrosis suppression in threatened trabeculectomy bleb failure produces good long term control of intraocular pressure without the risk of sight threatening complications. Br J Ophthalmol. 2002; 86: 1352-4.
51. Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol. 2007; 127: 514-25.
52. Chong RS, Jiang YZ, Boey PY, et al. Tear cytokine profile in medicated glaucoma patients: effect of monocyte chemoattractant protein 1 on early posttrabeculectomy outcome. Ophthalmol. 2010; 117: 2353-8.
53. McQuibban GA, Gong JH, Wong JP, et al. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood. 2002; 100: 1160-7.
54. Van den Steen PE, Proost P, Wuyts A, et al. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAPIII, PF-4, and GRO-α and leaves RANTES and MCP-2 intact. Blood. 2000; 96: 2673-81.